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The proteasome is a validated target for anticancer therapy, and proteasome inhibition is employed in the clinic for the treatment of tumors and hematological malignancies. Here, we describe crystal structures of the native human 20S proteasome and its complexes with inhibitors, which either are drugs approved for cancer treatment or are in clinical trials. The structure of the native human 20S proteasome was determined at an unprecedented resolution of 1.8 angstroms. Additionally, six inhibitor-proteasome complex structures were elucidated at resolutions between 1.9 and 2.1 angstroms. Collectively, the high-resolution structures provide new insights into the catalytic mechanisms of inhibition and necessitate a revised description of the proteasome active site. Knowledge about inhibition mechanisms provides insights into peptide hydrolysis and can guide strategies for the development of next-generation proteasome-based cancer therapeutics. P roteasomes play a major role in cytosolic and nuclear proteolysis and are central to cellular physiology and growth (1) (2) (3) (4) . The inhibition of proteasomes is proposed as an efficient strategy for restricting cancer growth. However, the development of new proteasome inhibitors is hampered by a lack of structural knowledge of ligand binding sites and by a lack of understanding of the biochemical mechanisms underlying proteasome inhibition. The proteasome is a large macromolecular complex (750 kD), with an overall architecture that is defined by four coaxially stacked heteroheptameric rings, the outer two consisting of a subunits (a1 to a7) and the inner two formed by b subunits (b1 to b7) (Fig. 1A) (1, 2, 5) . The b1, b2, and b5 subunits contain the proteolytic active sites with caspase-like, tryptic-like, and chymotryptic-like specificities, respectively (1, 2, 5) . Most of the current structural knowledge about the proteasome and its binding sites for inhibitors comes from studies of the yeast proteasome (1, 2) .
High-resolution structures of human 20S proteasomes are required to understand the chemical nature of proteasome inhibition at the atomic level. Although recently the first structures of the human 20S proteasome in complex with inhibitors were determined by x-ray crystallography and electron cryomicroscopy at 2.9 and 3.5 Å (6, 7), respectively, direct observation of the atomic details of inhibition was not possible.
To obtain structural information at higher resolution, we established an optimized and robust pipeline for the production, purification, and crystallization of human 20S proteasomes that generates large quantities of protein and allows hundreds of crystals to be grown that routinely diffract to high resolution. A series of technical improvements were essential to establish this pipeline, which we summarize as follows: (i) A chromatography-free purification procedure at constant ionic strength, employing polyethylene glycol (PEG) fractionation of HeLa lysates and density gradients [see the supplementary materials (SM)]. Gradient fractions are then precipitated and concentrated by PEG addition, yielding the finally purified protein preparation. (ii) Buffer conditions were optimized by Proteoplex that we recently developed (8) and is identical to the crystallization buffer. We thus obtained highly soluble and stable complexes with specific activity higher by a factor of 10 ( fig. S1 ) than that reported for previous human 20S proteasome preparations (9) . (iii) Crystals belong to space group P2 1 2 1 2 1 and grow to typical dimensions of 150 × 150 × 200 mm 3 in size within 20 hours of incubation at 18°C (Fig. 1C) . (iv) Postcrystallization treatments (see SM) yield complete, isotropic diffraction data sets to better than 2.0 Å resolution (Fig. 1D ) using "top-hat" beam profiles defined by a compound refractive lens (CRL) transfocator system on beamline P14 at the PETRA III storage ring (see SM).
Employing this pipeline, we first determined the native crystal structure of the complete human 20S proteasome at 1.8 Å resolution. Second, crystal structures of four previously uncharacterized inhibitor complexes of the human 20S proteasome with clinically relevant inhibitors were elucidated in the resolution range of 1.9 to 2.1 Å (table S2) , giving rise to a revised view of the inhibition chemistry.
For the native structure, final crystallographic maps revealed exceptionally clear electron densities for the entire particle and several ligands ( Fig. 2A) . The identity of many ions was validated by anomalous difference Fourier maps, partially in native crystals or in crystals, where the ligands in question were exchanged against anomalous scatterers (see SM). We were able to unambiguously assign 58 chloride, 15 magnesium, and 6 potassium ions, as well as several PEG molecules and more than 3500 localized water molecules. Given that the quality of electron density maps in previous studies of 20S proteasome crystals was severely affected by anisotropy in the diffraction of the respective crystals (5, 6, 9-11), we attribute the high quality of the electron density maps presented here to a large extent to far more isotropic diffraction. At 1.8 Å resolution, a number of functionally important differences with respect to the previously published 20S proteasome structures become visible. Notably, a solvent molecule, previously assigned as catalytic water (NUK) (5, 6, 9, 10), was identified as a chloride ion in all active sites (Figs. 2, B , C, and D). Soaking crystals grown in MgCl 2 with Mg(OAc) 2 leads to the replacement of chloride with water in the NUK position, which suggests that this solvent molecule acts as a vehicle for a proton shuttle rather than a nucleophile (see below). Three additional, localized water molecules (H 2 O-1, -2, and -3), which were not seen in earlier structures, are visualized in the proteasome active site. All inhibitors analyzed in this manuscript are described to have specificity for the b5 subunit; we will therefore restrict the discussion to this active site.
The most prominent differences with respect to previously determined structures were observed in the b5 active site of the 1.9 Å proteasomeOprozomib cocrystal structure. Oprozomib is an orally bioavailable epoxyketone inhibitor (12) that is in clinical trials for the treatment of advanced refractory or recurrent solid tumors (13) . Epoxyketone inhibitors are characterized by a short peptide core and a terminal a,b-epoxyketone dual electrophilic reactive warhead, which is the basis of their efficacy. Based on several cocrystal structures of epoxyketone inhibitors with yeast, mouse, and human 20S proteasomes (6, (9) (10) (11) 14) , it has been concluded that the g-OH of the proteasome active site Thr 1 reacts with the ketone moiety, whereas the N-terminal amino group of Thr 1 reacts irreversibly with the carbon atom in the a position of the epoxide (6, 9-11, 14) ( fig.  S2 ), allegedly resulting in a 1,4-morpholine (sixmembered) ring product.
After refinement of the Oprozomib-human 20S proteasome structure at 1.9 Å resolution (Fig. 3A) , we were unable to confirm the formation of the predicted 1,4-morpholine ring structure. Instead, electron density maps clearly revealed a larger ring-shaped electron density for the inhibitorThr 1 conjugate, providing space for an additional methylene group within the ring. The cyclic moiety visible in the inhibited state could be modeled as a 1,4-oxazepane (seven-membered) ring structure with the C6-methyl group oriented toward the inner, solvent-inaccessible side of the ring. The C6-OH moiety is on the solvent-exposed side overlaying the position, where the methanolic group of the 1,4-morpholine ring had been modeled previously (6, (9) (10) (11) 14) . Waters 1 to 3 are displaced by the bound inhibitor and, instead, an epoxyketonespecific water molecule (EK-H 2 O; EK designates epoxyketone) is hydrogen-bonded to the C6-OH moiety and to Thr 21 g-OH. This structure suggests that the inhibition reaction yielding a seven-ring product proceeds via nucleophilic attack by the N-terminal amine of the epoxide b carbon (Fig. 3A) and not the epoxide a carbon ( fig. S2 ), as previously reported (6, 9-11, 14) . This would have consequences not only for the mode of inhibition but also for the general reactivity of the proteasome active site. We therefore carried out a series of additional control experiments: (i) By soaking crystals with Mg(OAc) 2 before soaking with Oprozomib, we were able to ensure that the presence of a chloride ion in the NUK site is not responsible for sevenring formation ( fig. S3). (ii) A dose-series experiment performed with Oprozomib revealed that seven-ring formation was not caused by radiochemistry during x-ray data collection ( fig. S4 ).
(iii) Cocrystal structures of the natural product epoxyketone Epoxomicin showed electron densities perfectly matching the seven-ring model ( fig. S5 ), albeit at a lower resolution of 2.4 Å. (iv). We determined the structure of the 20S proteasome in complex with another natural product epoxyketone, Dihydroeponemycin, at 2.0 Å resolution. Dihydroeponemycin differs from Oprozomib and Epoxomicin by a substitution of the epoxide a carbon methyl group by a methanolic group (Fig. 3B) . If the N-terminal amino group of Thr 1 reacted with the epoxide a carbon, the reaction would yield a six-ring structure with a nonchiral center containing two methanolic groups ( fig. S6) . Instead, the electron density clearly shows a seven-ring structure similar to Oprozomib/Epoxomicin but with the C6-methanolic group on the inner side of the ring (Fig. 3B) , thus confirming the reaction of the Thr 1 N-terminal amine with the epoxide b carbon. The C6-methanol oxygen atom forms hydrogen bonds to Thr 21 g-OH and to Tyr 169 carbonyl, whereas the EK-H 2 O remains hydrogen-bonded to the C6-OH. (v) Competitive refinement by enforcing a six-ring linkage poorly fit the electron density and led to a model with severely distorted molecular geometry ( fig.  S7 ). These findings suggest that the efficacy of epoxyketone inhibitors lies in their ability to form 1,4-oxazepane (seven-membered) ring structures with the active site Thr To explore the structural implications of a six-ring linkage, we determined the structure of the human 20S proteasome inhibited by Z-LLY-Ketoaldehyde (15) at 2.1 Å resolution (Fig.  3C) . Here, the ring formation can proceed only via a carbon atom in the a position of the ketone. In these case, the electron density in the active site can indeed be unambiguously interpreted by a six-membered ring and reveals clear density for a hydroxyl group at the C5 position of the linkage (Fig. 3C) . We therefore conclude that inhibition by Z-LLY-Ketoaldehyde results in the formation of a 1,4-morpholine (six-membered) ring and not a 5,6-dihydro-2H-1,4-oxazine ring as reported previously (16) . Coordination of the 1,4-morpholine ring in the active site diverges substantially from that of a seven-ring (Fig. 3C) . The NUK chloride ion is absent, and a water molecule appears 1.2 Å away from the NUK site, where it hydrogen bonds to the Ser To address the putative role of H 2 O-3 in the inhibition mechanism, we determined the highresolution structures of human 20S proteasomes with boronic acid inhibitors, which mimic the first tetrahedral intermediate in protein cleavage (Fig. 4, A to C) . Boronic inhibitors constitute a particularly important class since Bortezomib was the first proteasome inhibitor approved in 2004 for the treatment of multiple myeloma (17) . Ixazomib was approved as an orally bioavailable inhibitor to treat the same disease in 2015 (18) , and Delanzomib is presently in clinical trials for this purpose and to treat autoimmune disease (19) . Specifically, we determined the 2.1 Å resolution structure of the Bortezomib-20S proteasome complex (Fig. 4A) , the 2.0 Å structure of the Ixazomib(MLN9708)-20S proteasome complex (Fig. 4B) , and the 2.0 Å structure of the Delanzomib(CEP-18770)-20S proteasome complex (Fig. 4C) . In all these cocrystal structures, the NUK chloride is exchanged against water, and H 2 O-1 and H 2 O-2 are displaced from the active site upon inhibitor binding. H 2 O-3, however, remains prominently hydrogen-bonded to the hydroxyl group of the boronic acid moiety, suggesting that it stabilizes the tetrahedral intermediate (Figs. 4, A, B , and C). Given these observations, two conclusions can be drawn: (i) the NUK solvent molecule resides on the opposite stereoface of the inhibitor and thus cannot support the cyclization step in the inhibition mechanism for epoxyketones and ketoaldehydes, and (ii) H 2 O-3 appears well positioned to play a role in this second step.
To better understand the proteasome inhibition mechanism, we performed cluster quantum chemical calculations on the basis of the crystal structures. Our results indicate that residues Asp 17 and Lys 33 cooperate to activate the Thr 1 -gOH nucleophile, whereas the NUK solvent molecule stabilizes the resulting tetrahedral oxyanion (figs. S8 and S9 and supplementary text). Second, we obtained full reaction pathways for both six-and seven-ring formation through a similar epoxide ring opening event ( fig. S10 and SM). The reaction bottleneck is this cyclization step of the inhibition mechanism, where we find that the seven-ring pathway is kinetically favored (by~18 kJ/mol) (Fig. 4D) . Thermodynamically, the six-ring product is more stable (by~30 kJ/mol) (Fig. 4D) , but the strain of the transition state results in a preferential sevenring formation (movies S1 and S2). We have found no evidence that the NUK solvent molecule could participate in this cyclization step due to its location at the opposite stereoface relative to the amine nucleophile. Instead, from the computed pathways and the boronic inhibitor cocrystal structures, H 2 O-3 likely serves as a proton shuttle in this step. We propose to refer to H 2 O-3 as CAT (for a catalytic water), given its likely role in the second step of the inhibition mechanism and the implicated role in peptide hydrolysis. Our kinetic measurements provide further evidence of the kinetic preference toward the seven-ring formation. The first-order inhibition rate constant for the ketoaldehyde is smaller by a factor of~20 than for Oprozomib and Dihydroeponemycin (Fig. 4E) . A residual rate of 3% of the maximum catalytic activity was only found in the case of seven-ring-forming epoxyketones, confirming that this product is thermodynamically less stable than the six-ring-forming ketoaldehyde. This is in agreement with our computed free energy differences.
The high-resolution structures of the human 20S proteasome described here were obtained as a result of numerous technical improvements in sample purification, crystal handling, and crystallographic data collection. Based on electron density maps at resolutions between 1.8 and 2.1 Å, we redefined the native and inhibited proteasome active site in terms of solvent molecules and covalent linkages with inhibitors. These findings were corroborated by cluster quantum chemical calculations and kinetic assays and are relevant for understanding the catalytic details of SCIENCE sciencemag.org The seven-ring reaction pathway proceeds from 0 through 1* to 1, whereas the six-ring reaction pathway proceeds from 0 through 2* to 2. (E) Kinetic analyses of the firstorder inactivation rate constants for the six-ring-forming Ketoaldehyde and for the seven-ring-forming Dihydroeponemycin and Oprozomib indicate that seven-ring formation occurs kinetically faster (fits shown in red). The residual rate of 3% of the maximum activity detected for epoxyketone inhibitors suggests that the seven-ring product is thermodynamically less stable, resulting in a reversible inhibition, which is in full agreement with the computed free reaction energy differences for the six and seven rings in (D).
proteasome activity and its inhibition chemistry. The insights into the atomic details of the catalytic center of the human 20S proteasome-an actual target of cancer therapeutics-provide important clues for the design of a new class of proteasome inhibitors. In particular, our results suggest that dual-electrophile inhibitors, where both electrophiles are in a b position to each other, would exhibit kinetically enhanced inhibition rates. Generally, with the tools described here, large numbers of such potential cancer therapeutics can be structurally analyzed at high resolution (several hundred per week could be feasible in an industrial setting), allowing for systematic exploration of ligand binding space toward improved efficacy and specificity. T he spatial organization of chromatin, such as chromatin domains, chromatin loops, associations of chromatin with nuclear structures, and chromosome territories, plays an important role in essential genome functions (1-6). However, many gaps remain in our understanding of the three-dimensional (3D) folding of individual chromosomes in the nucleus. Recently, chromosome-conformationcapture methods such as Hi-C (4, 7) have revealed a wealth of structural insights for interphase chromosomes. For example, chromatin is organized into topologically associating domains (TADs) or contact domains that are hundreds of kilobases (kb) in size (8) (9) (10) (11) . These domains tend to spatially segregate from each other (9, 12, 13) and, in Drosophila, correspond to the banding patterns of polytene chromosomes (14, 15) . At length scales from several hundred kilobases to several megabases, the power-law scaling of Hi-C contact frequency is consistent with a fractal-globule polymer model (7, 16) , whereas, within TADs, Hi-C contact maps are better described by a loop-extrusion model (17, 18) . Superresolution imaging shows that chromatin domains in different epigenetic states adopt distinct folding configurations with different power-law scaling properties (13) . Whether the ideal fractal-globule model can describe chromatin at length scales beyond several megabases remains an open question (19, 20) . Hi-C analyses have also revealed two multi-TAD compartments, compartments A and B, that are enriched with active and inactive chromatin, respectively (7, 21) . However, because the contact maps used to identify these compartments were derived from ensemble averaging of many chromosomes, it is unclear whether the A and B compartments are structures that exist in individual chromosomes inside single cells and, if so, how the two compartments are spatially arranged with respect to each other. To answer questions regarding the spatial organization of individual chromosomes requires methods that directly visualize the conformation of single chromosomes in single cells.
Fluorescence in situ hybridization (FISH) provides a powerful means to directly image the spatial organization of chromosomes, especially when used to simultaneously target two or more genomic loci (e.g., 19, 20, 22-24). In one effort, a three-color barcoding approach has been used to simultaneously label multiple chromatin loci to trace the conformation of a chromosome arm in Drosophila blastoderm embryos (24). Nonetheless, routine tracing of the complex 3D folding path of chromosomes has remained challenging because of the difficulties associated with simultaneously imaging and unambiguously identifying many genomic regions on interphase chromosomes. Here, we report a multiplexed FISH method that enables sequential imaging of many genomic regions for 3D tracing of individual chromosomes in the nucleus and the use of this method to study the spatial arrangements of TADs and compartments in chromosomes 20, 21, 22, and X of human diploid (XX) IMR90 cells.
